Zynerba Pharmaceuticals, Inc.
(NASDAQ : ZYNE)

( )
ZYNE After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
VRXValeant Pharmaceuticals International, Inc. -3.03%29.1214.1%$171.35m
HZNPHorizon Therapeutics Plc -3.23%90.265.5%$158.05m
ICLRICON plc -0.41%203.644.2%$123.01m
GWPHGW Pharmaceuticals Plc -0.17%218.536.1%$109.25m
CTLTCatalent, Inc. -1.87%108.532.1%$99.68m
UTHRUnited Therapeutics Corp. 0.05%203.8414.1%$93.37m
JAZZJazz Pharmaceuticals Plc -1.03%167.162.3%$87.00m
BHCBausch Health Cos., Inc. -3.03%29.120.0%$63.36m
ARGXargenx SE -2.46%274.800.0%$49.77m
SAVACassava Sciences, Inc. -2.47%33.990.0%$46.67m
PRGOPerrigo Co. Plc 0.36%41.776.9%$34.24m
SAGESAGE Therapeutics, Inc. 0.55%75.057.6%$33.53m
AMRNAmarin Corp. Plc 0.40%5.041.5%$28.09m
PCRXPacira Biosciences, Inc. 0.70%63.519.9%$27.32m
ICPTIntercept Pharmaceuticals, Inc. -0.44%20.1916.7%$26.38m

Company Profile

Zynerba Pharmaceuticals, Inc. engages in the provision of pharmaceutically-produced transdermal cannabinoid therapies. It focuses on research and development of rare and near-rare neuropsychiatric conditions. The firm offers Zygel product, which formulated as a permeation-enhanced gel for transdermal delivery. The company was founded by Audra L. Stinchcomb on January 31, 2007 and is headquartered in Devon, PA.